Список литературы

1. Vassallo P., Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298(11): 1312-22.

2. Singh B.N. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol. 2008 Oct; 52(4): 300-5.

3. Chazov E.I., Dedov I.I. Cardiac and endocrine aspects of amiodarone therapy in modern practice of heart arrhythmia disorders treatment. Doctors manual. Moscow, 2005. Russian. (Чазов Е.И., Дедов И.И. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритмов сердца. Пособие для врачей. Москва, 2005).

4. Bogazzi F., Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010; 95: 2529 - 2535

5. Martino E., Bartalena M.E., Bogazzi F., Braverman L.E. The effects of amiodarone on the thyroid. Endocr Rev. 2001; 22: 240 - 254.

6. Ahmed S., Van Gelder I.C., Wiesfeld ACP et al. Determinations and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011; 75: 388 - 394.

7. Beddows S.A., Page S.R., Taylor A.H., et al Cytotoxic Effects of Amiodarone and Desethylamiodarone on Human Thyrocytes. Biochem Pharmacol. 1989; 38: 4397-403.

8. Holt D.W., Tucker G.T., Jackson P.R., Storey G.C. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct; 106(4 Pt 2): 840-7.

9. Basaria S., Cooper D.S. Amiodarone and the thyroid. Am J Med. 2005; 118: 706-14.

10. Fukuchi H., Nakashima M., Araki R., et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. J Clin Pharm Ther. 2009; 34: 329-36.

11. Trip M.D., Wiersinga W., Plomp T.A. Incidence, predictability, and pathogenesis of amiodarone induced thyrotoxicosis and hypothyroidism. Am J Med. 1991; 91: 507 - 511.

12. Yamato M., Wada K., Hayashi T. et al. Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction. Clin Drug Investig. 2018; 38(1): 39 - 48.

13. Sviridenko N.Yu, Platonova N.M., Molashenko N.V. et al. Endocrine aspects of amiodarone therapy in clinical practice. (Follow-up and treatment algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012; (2): 63 - 71. Russian. (Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В. и др. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский кардиологический журнал. 2021; 2: 63 - 71.

14. Lambert M.J., Burger A.G., Galeazzi R.L., Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 mono- deiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982; 55: 1058 - 1065.

15. Mel'nichenko G.A., Sviridenko N.Yu, Molashenko N.V. et al. Amiodarone-induced thyroid dysfunction: pathigenesis, diagnosis, treatment. Review. Terapevticheskiy arkhiv. 2003; 75 (8): 92-6. Russian. (Мельниченко Г.А., Свириденко Н.Ю., Молашенко Н.В. и др. Индуцированная амиодароном дисфункция щитовидной железы (патогенез, диагностика, лечение). Обзор. Терапевтический архив. 2003; 75(8): 92 - 96).

16. Tanda M.L., Piantanida E., Lai A. et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008; 69: 812 - 818.

17. Raghavan R.P., Taylor P.N., Bhake R. et al. Amiodarone-induced thyrotoxicosis: an overview of UK management. Clin Endocrinol (Oxf). 2012; 77: 936 - 937.

18. Platonova N.M., Molashenko N.V., Sviridenko N.Yu, et al. Amiodarone- associated thyroid dysfunction. Prevalence and correction possibilities. Cardiology. 2004; 10: 32 - 38. Russian. (Платонова Н.М., Молашенко Н.В., Свириденко Н.Ю. и др. Амиодарон-ассоциированная дисфункция щитовидной железы. Частота развития и возможности коррекции. Кардиология. 2004; 10: 32 - 38).

19. Zhong B., Wang Y., Zhang G., Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology. 2016; 134: 366 - 371.

20. Rizzo L.F.L., Mana D.L., Serra H.A. Drug-induced hypothyroidism. MEDICINA (Buenos Aires) 2017; 77: 394 - 404.

21. Nademanee K., Piwonka R.W., Singh B.N., Hershman J.M. Amiodarone and thyroid function. Progr Cardiovasc Dis. 1989; 31(6): 427-37.

22. Bogazzi F., Tomisti L., Bartalena L. et al. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012; 35: 340 - 348.

23. Batcher E.L., Tang X.C., Singh B.N., et al. (SAFE-T Investigators.) Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007; 120: 880 - 885.

24. Benjamens S., Dullaart R.P.F., Sluiter W.J., et al. The clinical value of regular thyroid function tests during amiodarone treatment. European J Endocrinol. 2017; 177: 9 - 14.

25. Serdiuk S.E., Bakalov S.A., Golitsyn S.P., et al. Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodarone. Terapevticheskiy Arkhiv. 2005; 77 (10): 33 - 39. Russian. (Сердюк С.Е., Бакалов С.А., Голицын С.П. и др. Частота возникновения и предикторы развития амиодарон-ассоциированных дисфункций щитовидной железы. Терапевтический архив. 2005; (10): 33 - 39).

26. Bartalena L.A., Bogazzi F.B., Chiovato L.C. et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018; 7: 55 - 66.

27. Grineva E.N., Dora S.V., Malahova T.V., Malahova Z.L. Amiodarone impact on thyroid structure and function. Problems of endocrinology. 2008; 54(3): 17 - 21. Russian. (Гринева Е.Н., Дора С.В. Малахова Т.В., Малахова З.Л. Влияние амиодарона на структуру и функцию щитовидной железы. Проблемы эндокринологии. 2008; 54 (3): 17 - 21).

28. Connolly S.J. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100: 2025 - 2034.

29. Doyle J.F., Ho K.M. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis. Mayo Clin Proc. 2009; 84: 234 - 242.

30. Cohen-Lehman J., Dahl P., Danzi S. et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010; 6: 34 - 41.

31. Elnaggar M.N., Jbeili K., Nik-Hussin N. et al. Amiodarone-induced thyroid dysfunction: a clinical update. Exp Clin Endocrinol Diabetes. 2018 Jun; 126(6): 333 - 341.

32. Unger J., Lambert M., Jonckheer M.H., Denayer P. Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. J Intern Med 1993; 233: 435 - 443.

33. Raber W. et al. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid 2002; Vol. 12(8): 725 - 731.

34. Tomisti L., Rossi G., Bartalena L., Martino E., Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014; 171: 363-8.

35. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013; 9(12): 724 - 734.

36. Grebe S.K., Kahaly G.J. Laboratory testing in hyperthyroidism. Am J Med. 2012; 125(9): S2.

37. Kahaly G.J., Olivo P.D. Graves' disease. N Engl J Med. 2017; 376(2): 184

38. Kahaly G.J., Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017; 8: 28

39. Tozzoli R., Bagnasco M., Giavarina D., Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012; 12(2): 107 - 113

40. Bogazzi F., Bartalena L., Dell'Unto E. et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007; 67: 533 - 537.

41. Maqdasy S., Batisse-Lignier M., Auclair C. et al. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol. 2016; 117: 1112 - 1116.

42. Ulupova E.O., Bogdanova G.A., Karonova T.L., Grineva E.N. Serum free thyroid hormones ratio in amiodarone-induced thyrotoxicosis types 1 and 2. Translational Medicine. 2018; 5(3): 28 - 35. Russian. (Улупова Е.О., Богданова Г.А., Каронова Т.Л., Гринева Е.Н. Соотношение свободных тиреоидных гормонов в сыворотке крови больных амиодарон-индуцированным тиреотоксикозом 1 и 2 типов. Трансляционная медицина. 2018; 5(3): 28 - 35).

43. Tomisti L., Urbani C., Rossi G. et al. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2016; 39: 585 - 591.

44. Sriphrapradang C., Bhasipol A. Differentiating Graves" disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Annals of Medicine and Surgery. 2016; 10: 69 - 72.

45. Bartalena L., Brogioni S., Grasso L. et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996; 81: 2930-3.

46. Smith T.J., Hegedus L: Graves' disease. N Engl J Med. 2016; 375: 1552 - 1565

47. Goichot B., Bouee S., Castello-Bridoux C., Caron P.: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017; 6(3): 152 - 159

48. Kwak J.Y., Han K.H., Yoon J.H., Moon H.J., Son E.J., Park S.H., Jung H.K., Choi J.S., Kim B.M., Kim E.K. Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology. 2011; 260(3): 892 - 899

49. Дедов И.И., Мельниченко Г.А., Свириденко Н.Ю., Платонова Н.М. Диагностика, профилактика и лечение ятрогенных йодиндуцированных заболеваний щитовидной железы. Вестник РАМН. 2006; 2: 15 - 22

50. Theodoraki A., Vanderpump M.P.J. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016; 84: 172 - 176.

51. Loy M., Perra E., Melis A. et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol. 2007; 48: 628 - 634.

52. Piga M., Cocco M.C., Serra A. et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008; 159: 423 - 429.

53. Wong R., Cheung W., Stockigt J.R. et al. Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Internal Medicine Journal 2003; 33: 420 - 426.

54. Bogazzi F., Bartalena L., Brogioni S. et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997; 7: 541 - 545.

55. Bogazzi F., Martino E., Dell'Unto E. et al. Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation. 2003; 26: 635 - 640.

56. Eaton S.E.M., Euinton H.A., Newman C.M. et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002; 56: 33 - 8.

57. Daniels G.H. Amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism. 2001; 86: 3 - 8.

58. Pattison D.A., Westcott J., Lichtenstein M. et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun. 2015; 36: 356 - 362.

59. Wang J. and Zhang R. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017; 90: 20160836.

60. Censi S., Bodanza V., Manso J. et al. Amiodarone-induced thyrotoxicosis differential diagnosis using 99mTc-SestaMIBI and target-to-background ratio (TBR). Clin Nucl Med. 2018; 43: 65 - 662.

61. Oki G.S.R., Zantut-Wittmann D.E., Guariento M.H. et al. Tc-99m Sestamibi thyroid imaging in patients on chronic amiodarone treatment. Comparison with Tc-99m pertechnetate imaging. Clin Nucl Med. 2010; 35: 223 - 227.

62. Souto S.B., Fernandes H., Matos M.J., et al. Importance of (99)mtC-sestaMIBI thyroid scan in a case of amiodarone induced thyrotoxicosis. Arquivos brasileiros de endocrinologia e metabologia. 2011; 55: 486 - 489.

63. Eskes S.A., Wiersinga W.M. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23: 735 - 751.

64. Osman F., Franklyn J.A., Sheppard M.C. et al Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. 2002; 105: 1275 - 1277.

65. Bogazzi F., Tomisti L., Rossi G. et al. Glucocorticoids are preferable to thionamides as first- line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab. 2009; 94: 3757 - 3762.

66. Braverman L.E., He X., Pino S. et al. The effect of perchlorate, thiocyanate, and nitrate on thyroid function in workers exposed to perchlorate long-term. J Clin Endocrinol Metab. 2005; 90(2): 700 - 6.

67. Shubert L., Bricaire L., Groussin L. Amiodarone-induced thyrotoxicosis. Ann Endocrinol (Paris). 2020; Apr 29: S0003-4266(20)30066-4. Online ahead of print

68. Martino E., Aghini-Lombardi F., Mariotti S et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf). 1987 Feb; 26(2): 227-37.

69. Dickstein G., Shechner C., Adawi F. et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med. 1997 May; 102(5): 454-8.

70. Papi G., Corsello S.M., Pontecorvi A. Clinical concepts on thyroid emergencies. Front Endocrinol (Lausanne). 2014 Jul 1; 5: article 102(1 - 9).

71. Campi I., Perego G.B., Ravoli A., et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. European Journal of Endocrinology. 2019; 181: 519 - 524.

72. Cappellani D., Urbani C., Manetti L., et al. Effect of high dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone induced thyrotoxicosis: an exploratory study. Journal of Endocrinological Investigation. 2020; Apr 16: Published online 16 April 2020.

73. Gough J., Gough I.R. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg. 2006; 30: 1957 - 1961.

74. Kaderli R.M., Fahrner R., Christ E.R. et al. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes. 2016; 124: 45 - 48.

75. Hamoir E., Meurisse M., Defechereux T. et al. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective? World J Surg. 1998; 22: 537 - 542.

76. Mulligan D.C., McHenry C.R., Kinney W. et al. Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. Surgery. 1993; 114: 1114 - 1119.

77. Meerwein C., Vital D., Greutmann M et al. Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery? HNO. 2014; 62: 100 - 105.

78. Cappellani D., Papini P., Pingitore A. et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxocosis. J Clin Endocrinol Metab. 2020 Jan; 105(1): 242 - 251.

79. Houghton S.G., Farley D.R., Brennan M.D. et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg. 2004; 28: 1083 - 1087.

80. Samaras K., Marel G.M. Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. Clin Endocrinol. 1996; 45: 365 - 368.

81. Diamond T., Rajagopal R., Ganda K. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Internal Medicine Jouranal. 2004; 34: 369 - 370.

82. Zhu L., Zainudin S., Kaushik M. et al. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinology, diabetes and metabolism. Case reports. ID: 16-0039; July 2016 DOI: 10.1530/EDM-16-003

83. Tonnelier A., J. de Filette, Ann De Becker et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J. 2017; 6: 108 - 112.

84. Goldschlager N., Epstein A.E., Naccarelli G. et al. Practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007; 4: 1250 - 1259.

85. Siddoway L.A. Amiodarone: Guidelines for Use and Monitoring. American family physician. 2003; 68: 2189 - 2196.

86. Trohman R.G., Sharma P.S., McAninch E.A., Bianco A.C. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019 July; 29(5): 285 - 295.

87. Philippou G., Koutras D.A., Piperingos G. et al. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf). 1992; 36: 573-8.

88. Eng P.H., Cardona G.R., Fang S.L., et al. Escape from the acute Wolff Chaikoff effects is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999; 140: 3404-10.

89. Rosene M.L., Wittmann G., Drigo R.A. et al. Inhibition of the Type 2 Iodothyronine Deiodinase Underlies the Elevated Plasma TSH Associated with Amiodarone Treatment. Endocrinology. 2010 Dec; 151(12): 5961 - 5970.

90. Kryukov E.V., Potekhin N.P., Fursov A.N. et al. Крюков Algorithm of management of patients treated with amiodarone depending on thyroid functional state. Clinical Medicine. 2017; 95(10): 901 - 904. Russian. Крюков Е.В., Потехин Н.П., Фурсов А.Н. и др. Алгоритм ведения пациентов, получающих амиодарон, в зависимости от функционального состояния щитовидной железы. Клиническая медицина. 2017; 95(10): 901 - 904.

91. Young R., Worthley L.I. G. Diagnosis and management of thyroid disease and the critically ill patient // Critical Care and Resuscitation. - 2004. - Т. 6. - N. 4. - С. 295 - 305.